Reducing dose to the lungs through loosing target dose homogeneity requirement for radiotherapy of non small cell lung cancer

被引:9
作者
Miao, Junjie
Yan, Hui
Tian, Yuan
Ma, Pan
Liu, Zhiqiang
Li, Minghui
Ren, Wenting
Chen, Jiayun
Zhang, Ye
Dai, Jianrong [1 ]
机构
[1] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Radiat Oncol, Beijing, Peoples R China
来源
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS | 2017年 / 18卷 / 06期
基金
中国国家自然科学基金;
关键词
IMRT; non small cell lung cancer; plan optimization; target dose homogeneity; treatment planning; INTENSITY-MODULATED RADIOTHERAPY; STEREOTACTIC BODY RADIOTHERAPY; TUMOR-CONTROL PROBABILITY; RADIATION PNEUMONITIS; NSCLC PATIENTS; IMRT; VOLUME; THERAPY; DISTRIBUTIONS; PARAMETERS;
D O I
10.1002/acm2.12200
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
It is important to minimize lung dose during intensity-modulated radiation therapy (IMRT) of nonsmall cell lung cancer (NSCLC). In this study, an approach was proposed to reduce lung dose by relaxing the constraint of target dose homogeneity during treatment planning of IMRT. Ten NSCLC patients with lung tumor on the right side were selected. The total dose for planning target volume (PTV) was 60 Gy (2 Gy/fraction). For each patient, two IMRT plans with six beams were created in Pinnacle treatment planning system. The dose homogeneity of target was controlled by constraints on the maximum and uniform doses of target volume. One IMRT plan was made with homogeneous target dose (the resulting target dose was within 95%-107% of the prescribed dose), while another IMRT plan was made with inhomogeneous target dose (the resulting target dose was more than 95% of the prescribed dose). During plan optimization, the dose of cord and heart in two types of IMRT plans were kept nearly the same. The doses of lungs, PTV and organs at risk (OARs) between two types of IMRT plans were compared and analyzed quantitatively. For all patients, the lung dose was decreased in the IMRT plans with inhomogeneous target dose. On average, the mean dose, V5, V20, and V30 of lung were reduced by 1.4 Gy, 4.8%, 3.7%, and 1.7%, respectively, and the dose to normal tissue was also reduced. These reductions in DVH values were all statistically significant (P < 0.05). There were no significant differences between the two IMRT plans on V25, V30, V40, V50 and mean dose for heart. The maximum doses of cords in two type IMRT plans were nearly the same. IMRT plans with inhomogeneous target dose could protect lungs better and may be considered as a choice for treating NSCLC.
引用
收藏
页码:169 / 176
页数:8
相关论文
共 50 条
  • [31] Impact of dose to lung outside the planning target volume on distant metastasis or progression after SBRT for early-stage non-small cell lung cancer
    Hughes, Ryan T.
    Steber, Cole R.
    Jacobson, Travis J.
    Farris, Michael K.
    RADIOTHERAPY AND ONCOLOGY, 2021, 159 : 28 - 32
  • [32] Functional dose-volume histograms for predicting radiation pneumonitis in locally advanced non-small cell lung cancer treated with late-course accelerated hyperfractionated radiotherapy
    Wang, Dongqing
    Li, Baosheng
    Wang, Zhongtang
    Zhu, Jian
    Sun, Hongfu
    Zhang, Jian
    Yin, Yong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (05) : 1017 - 1022
  • [33] Spect-guidance to Reduce Radioactive Dose to Functioning Lung for Stage III Non-small Cell Lung Cancer
    Wang, Zhong-Tang
    Wei, Li-Li
    Ding, Xiu-Ping
    Sun, Ming-Ping
    Sun, Hong-Fu
    Li, Bao-Sheng
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (02) : 1061 - 1065
  • [34] Simple method for evaluating achievement degree of lung dose optimization in individual patients with locally advanced non-small cell lung cancer treated with intensity modulated radiotherapy
    Abe, Takanori
    Iino, Misaki
    Saito, Satoshi
    Aoshika, Tomomi
    Ryuno, Yasuhiro
    Ohta, Tomohiro
    Igari, Mitsunobu
    Hirai, Ryuta
    Kumazaki, Yu
    Miura, Yu
    Kaira, Kyoichi
    Kagamu, Hiroshi
    Noda, Shinei
    Kato, Shingo
    THORACIC CANCER, 2022, 13 (20) : 2890 - 2896
  • [35] Accurate prediction of target dose-escalation and organ-at-risk dose levels for non-small cell lung cancer patients
    Petit, Steven F.
    van Elmpt, Wouter
    RADIOTHERAPY AND ONCOLOGY, 2015, 117 (03) : 453 - 458
  • [36] Evaluation of tumor motion effects on dose distribution for hypofractionated intensity-modulated radiotherapy of non-small-cell lung cancer
    Kang, Hyejoo
    Yorke, Ellen D.
    Yang, Jie
    Chui, Chen-Shou
    Rosenzweig, Kenneth E.
    Amols, Howard I.
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2010, 11 (03): : 78 - 89
  • [37] Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
    Ma, Jie-Tao
    Sun, Li
    Sun, Xin
    Xiong, Zhi-Cheng
    Liu, Yang
    Zhang, Shu-Ling
    Huang, Le-Tian
    Han, Cheng-Bo
    RADIATION ONCOLOGY, 2017, 12
  • [38] Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques
    Nowicka, Zuzanna
    Kuna, Kasper
    Laszczych, Mateusz
    Lazar-Poniatowska, Malgorzata
    Sobocki, Bartosz Kamil
    Stawiski, Konrad
    Dabrowski, Michal
    Bruski, Konrad
    Zieba, Adam
    Pajdzinski, Mateusz
    Staniewska, Emilia
    Miszczyk, Marcin
    Paganetti, Harald
    Fendler, Wojciech
    Tomasik, Bartlomiej
    PHYSICS & IMAGING IN RADIATION ONCOLOGY, 2024, 30
  • [39] Motion Management for Radical Radiotherapy in Non-small Cell Lung Cancer
    Cole, A. J.
    Hanna, G. G.
    Jain, S.
    O'Sullivan, J. M.
    CLINICAL ONCOLOGY, 2014, 26 (02) : 67 - 80
  • [40] Dose escalation for non-small cell lung cancer: Analysis and modelling of published literature
    Partridge, Mike
    Ramos, Monica
    Sardaro, Angela
    Brada, Michael
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 (01) : 6 - 11